190 related articles for article (PubMed ID: 8162163)
1. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis.
Faber J; Galløe AM
Eur J Endocrinol; 1994 Apr; 130(4):350-6. PubMed ID: 8162163
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
Guo CY; Weetman AP; Eastell R
Clin Endocrinol (Oxf); 1997 Mar; 46(3):301-7. PubMed ID: 9156039
[TBL] [Abstract][Full Text] [Related]
3. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women.
Baqi L; Payer J; Killinger Z; Hruzikova P; Cierny D; Susienkova K; Langer P
Endocr Regul; 2010 Apr; 44(2):57-63. PubMed ID: 20429634
[TBL] [Abstract][Full Text] [Related]
4. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
Reverter JL; Holgado S; Alonso N; Salinas I; Granada ML; Sanmartí A
Endocr Relat Cancer; 2005 Dec; 12(4):973-81. PubMed ID: 16322336
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy.
Nuzzo V; Lupoli G; Esposito Del Puente A; Rampone E; Carpinelli A; Del Puente AE; Oriente P
Gynecol Endocrinol; 1998 Oct; 12(5):333-7. PubMed ID: 9859026
[TBL] [Abstract][Full Text] [Related]
6. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine.
Stall GM; Harris S; Sokoll LJ; Dawson-Hughes B
Ann Intern Med; 1990 Aug; 113(4):265-9. PubMed ID: 2375563
[TBL] [Abstract][Full Text] [Related]
7. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women.
Lehmke J; Bogner U; Felsenberg D; Peters H; Schleusener H
Clin Endocrinol (Oxf); 1992 May; 36(5):511-7. PubMed ID: 1617803
[TBL] [Abstract][Full Text] [Related]
8. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis.
Franklyn JA; Betteridge J; Holder R; Sheppard MC
Thyroid; 1995 Oct; 5(5):359-63. PubMed ID: 8563472
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy.
Garton M; Reid I; Loveridge N; Robins S; Murchison L; Beckett G; Reid D
Clin Endocrinol (Oxf); 1994 Dec; 41(6):747-55. PubMed ID: 7889610
[TBL] [Abstract][Full Text] [Related]
10. Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis.
Hawkins F; Rigopoulou D; Papapietro K; Lopez MB
Calcif Tissue Int; 1994 Jan; 54(1):16-9. PubMed ID: 8118747
[TBL] [Abstract][Full Text] [Related]
11. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.
De Rosa G; Testa A; Maussier ML; Callà C; Astazi P; Albanese C
Horm Metab Res; 1995 Nov; 27(11):503-7. PubMed ID: 8770627
[TBL] [Abstract][Full Text] [Related]
12. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
Ongphiphadhanakul B; Puavilai G; Rajatanavin R
J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for non-toxic goitre.
De Rosa G; Testa A; Giacomini D; Carrozza C; Astazi P; Caradonna P
Clin Endocrinol (Oxf); 1997 Nov; 47(5):529-35. PubMed ID: 9425392
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?
Földes J; Tarján G; Szathmari M; Varga F; Krasznai I; Horvath C
Clin Endocrinol (Oxf); 1993 Nov; 39(5):521-7. PubMed ID: 8252739
[TBL] [Abstract][Full Text] [Related]
16. Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women.
Fujiyama K; Kiriyama T; Ito M; Kimura H; Ashizawa K; Tsuruta M; Nagayama Y; Villadolid MC; Yokoyama N; Nagataki S
Thyroid; 1995 Feb; 5(1):13-7. PubMed ID: 7787427
[TBL] [Abstract][Full Text] [Related]
17. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women.
Faber J; Jensen IW; Petersen L; Nygaard B; Hegedüs L; Siersbaek-Nielsen K
Clin Endocrinol (Oxf); 1998 Mar; 48(3):285-90. PubMed ID: 9578817
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral density in postmenopausal women treated with L-thyroxine.
Adlin EV; Maurer AH; Marks AD; Channick BJ
Am J Med; 1991 Mar; 90(3):360-6. PubMed ID: 2003518
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
[TBL] [Abstract][Full Text] [Related]
20. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
Diamond T; Nery L; Hales I
J Clin Endocrinol Metab; 1991 Jun; 72(6):1184-8. PubMed ID: 2026740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
